Table 1.
Patient demography.
| Characteristic | All (n = 30) | Grade II (n = 15) | Grade III (n = 15) | p-value |
|---|---|---|---|---|
| Age | 61.1 ± 11.5 | 61.0 ± 12.0 | 61.2 ± 11.3 | 0.9628 |
| Body mass index (BMI) | 30.4 ± 6.4 | 30.4 ± 6.6 | 30.3 ± 6.6 | 0.9771 |
| Tumour size (cm) | 2.5 ± 0.8 | 2.4 ± 0.9 | 2.5 ± 0.7 | 0.7650 |
| Tumour volume (cm3)a | 20.0 ± 21.3 | 20.3 ± 19.2 | 19.6 ± 23.9 | 0.9335 |
| Nottingham prognostic index (NPI) | 4.41 (3.62–4.56) | 3.62 (3.46–4.29) | 4.50 (4.44–5.02) | 0.0001* |
| Tumour type | ||||
| pTNM Stage | ||||
| I | 5 | 3 | 2 | 1.000 |
| II | 25 | 12 | 13 | |
| Lymphovascular invasion (LVI) | 17 | 9 | 8 | 1.000 |
| Lymph node involvement | 8 | 4 | 4 | 1.000 |
| Oestrogen receptor (ER+) | 22 | 13 | 9 | 0.215 |
| Human epidermal growth factor receptor 2 (HER2+) | 6 | 2 | 4 | 0.651 |
| Triple-negative breast cancer (TNBC) | 7 | 1 | 6 | 0.080 |
Patient demography and clinical histopathological findings of excised breast tumours are shown for each group and the entire cohort. Quantitative data are expressed as mean and standard deviation (apart from Nottingham Prognostic Index where median and interquartile range are shown), while qualitative data expressed as number of positive cases.
*Significant findings (p < 0.05) are marked.
aTumour volume extracted from T2-weighted MRI.